Proteomics International Laboratories Ltd. announced that it has assembled a team of world leading clinicians specialising in nephrology and endocrinology to advise the Company on its clinical and commercial initiatives towards a successful launch of the PromarkerD test for diabetic kidney disease to physicians globally. The clinicians--from the United States, Europe and Australia--are global experts in diabetes technology and care, and influential key opinion leaders in their respective fields. Together, they form a world class clinical advisory board to offer expert opinion on the best strategies for the market rollout of PromarkerD from a doctor's viewpoint.

The engagement of the Clinical Advisory Board builds upon a powerful clinical utility study that demonstrated the PromarkerD predictive test for diabetic kidney disease can help inform doctors' treatment decisions and improve clinical outcomes for patients with type 2 diabetes. Ultimately it is physicians that will order the PromarkerD test for their patients and generate sales for Proteomics International. The Clinical Advisory Board comprises seven respected physicians, researchers and thought leaders, from some of the world's top hospitals and universities specialising in the care of diabetes and its complications.

Clinical Advisory Board includes: Professor Tim Davis- Professor Tim Davis is a consultant physician and endocrinologist at Fremantle Hospital, and professor of medicine at The University of Western Australia; Dr. Ele Ferrannini-he is a professor of medicine at the University of Pisa, an adjunct clinical professor of medicine at the University of Texas Health Science Center, and a senior research associate at the National Research Council's Institute of Clinical Physiology; Dr. David Kerr-he is the Director of Research and Innovation at the Sansum Diabetes Research Institute in Santa Barbara, California. Prior to this, he was Consultant Physician at Bournemouth Diabetes; Clinical Professor David Klonoff-he is a Clinical Professor of Medicine at the University of California at San Francisco and an endocrinologist specialising in bioengineered solutions for people with diabetes; Associate Professor Michael Shanik-he is managing partner at Endocrine Associates of Long Island, PC and a clinical associate professor at Stony Brook University Hospital, New York; Professor Merlin Thomas- Professor Merlin Thomas is a nephrologist, scientist and program leader in the Department of Diabetes at Monash University. He is founder and chief scientific officer of RAGE Biotech Ltd; Dr. Alexander Turchin-Dr. Alexander Turchin is the director of quality for the division of endocrinology at Brigham and Women's Hospital and an associate professor of medicine at Harvard Medical School.